Monascus - Beijing Peking University WBL Biotech
Alternative Names: High strength monascus - Luye Pharma; Lipascor; LY-02404; Red yeast rice extract - Beijing Peking University WBL Biotech; WPU; Xuezhikang; Xuezhikang (XZK) - Luye Pharma Group; Xuezhikang - Beijing Peking University WBL BiotechLatest Information Update: 20 Sep 2023
At a glance
- Originator Beijing Peking University WBL Biotech
- Developer AstraZeneca; Beijing Peking University WBL Biotech
- Class Antihyperlipidaemics; Herbal medicines
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia
- Registered Lipid metabolism disorders
- Discontinued Hypercholesterolaemia
Most Recent Events
- 29 Aug 2023 Registered for Lipid metabolism disorders in Uzbekistan (PO)
- 28 Sep 2022 Discontinued - Phase-II for Hypercholesterolaemia in China (PO) (Luye pharma pipeline, September 2022)
- 28 Sep 2022 No development reported - Phase-II for Hyperlipidaemia in USA (PO) (Luye pharma pipeline, September 2022)